Appetite Control Supplement Recalled Due to Confirmed DMAA

Published Online: Monday, August 11, 2014
Follow Pharmacy_Times:
Regeneca Worldwide, a division of VivaCeuticals, Inc, has launched a voluntary nationwide recall of RegeneSlim following an FDA analysis that confirmed the presence of DMAA in the appetite control dietary supplement.  

Also known as 1,3-dimethylamylamine, methylhexanamine, or geranium extract, DMAA is commonly used as a stimulant, pre-workout, and weight loss ingredient in dietary supplements. DMAA is potentially dangerous to health because it can narrow blood vessels and arteries, which can cause a rise in blood pressure or other cardiovascular problems, such as shortness of breath, arrhythmias, tightening in the chest, and heart attack, the FDA warned in the recall announcement.

As a result, consumers who have purchased RegeneSlim from lot numbers EX0616R15814 and 11414RE5516 are urged to immediately stop using the product and return it to the place of purchase for a full exchange. Consumers should also contact their physician or health care provider if they experience any problems that may be related to taking or using RegeneSlim. Although no illnesses related to the supplement have been reported to date, Regeneca continues its investigation as to what caused the problem.

RegeneSlim is purchased by and distributed through a direct sales force within the United States and Puerto Rico, and through online sales, for both personal consumption and retail sales. The supplement is packaged in green and white sachets that contain 2 capsules, and the word “RegeneSlim” is displayed prominently on the front of each sachet.

Adverse reactions or quality problems experienced with the use of RegeneSlim may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.
Related Articles
The rate of type 1 diabetes mellitus among non-Hispanic white youth increased significantly over an 8-year period.
As a result of confusing sensations of breathlessness with asthma symptoms, overweight and obese children tend to report poorer asthma control and overuse rescue medications.
Supplements sold after FDA recalls are still contaminated with banned pharmaceutical ingredients.
Current risk assessment strategies for reducing fractures related to osteoporosis among women fail to accurately predict who will experience major osteoporotic injuries.
Latest Issues
$auto_registration$